View Clinical Trial (Medical Research Study)

A Randomized, Double Blind, Placebo Controlled Phase 2 Study To Assess The Immune Response Following Administration Of Influenza And Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving Cp-690,550 Or Placebo Cp-690,550 With And Without Ba

---

Conditions:		Rheumatoid Arthritis
Purpose:		A Randomized, Double Blind, Placebo Controlled Phase 2 Study To assess the Immune Response Following Administration of Influenza and Pneumococcal Vaccines to Subjects with Rheumatoid Arthritis receiving CP-690,550 with and Without background Methotrexate
Study Summary:
Criteria:		Inclusion Criteria: - The subject must meet the American College of Rheumatology (ACR) classification criteria for the diagnosis of RA by satisfying at least four of the seven criteria. - The subject must have active disease at both screening and baseline Exclusion Criteria: - History of any documented influenza or pneumococcal infection within the last 3 months. - Receipt of any vaccine within 1 month prior to the initial study drug administration (CP-690,550 or placebo CP-690,550). - If a subject has received an influenza vaccine within 6 months or a pneumococcal vaccine within 5 years of initial study drug administration.
NCT ID:		NCT01359150
Primary Contact:		Study Director Pfizer CT.gov Call Center Pfizer Pfizer CT.gov Call Center Phone: 1-800-718-1021
Backup Contact:		N/A
Location Contact:		Tupelo, Mississippi 38801 United States There is no listed contact information for this specific location. Site Status: Not yet recruiting

---

---